Improving the decision to switch from first to second-line therapy in multiple sclerosis: a dynamic scoring system

Archive ouverte

Sabathe, C. | Casey, Romain | Vukusic, S. | Leray, Emmanuelle | Mathey, G. | de Seze, J. | Ciron, J. | Wiertlewski, S. | Ruet, A. | Pelletier, J. | Zephir, H. | Michel, L. | Lebrun-Frenay, C. | Moisset, X. | Thouvenot, Eric | Camdessanche, J. -P. | Bakchine, Serge | Stankoff, B. | Al Khedr, A. | Cabre, P. | Maillart, E. | Berger, E. | Heinzlef, O. | Hankiewicz, K. | Moreau, T. | Gout, O. | Bourre, B. | Wahab, A. | Labauge, Pierre, M. | Montcuquet, A. | Defer, G. | Maurousset, A. | Maubeuge, N. | Dalia, D. Boulos | Ben Nasr, H. | Nifle, C. | Casez, O. | Laplaud, David-Axel | Foucher, Yohann

Edité par CCSD ; SAGE Publications -

International audience. Background - In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression. Objective - We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy. Methods - Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs). Results - From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09-0.22) for the waiting group and 0.40 (95% CI 0.32-0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30-0.46) and 0.44 (95% CI 0.37-0.52), respectively. Conclusions - By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse.

Consulter en ligne

Suggestions

Du même auteur

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Archive ouverte | Lefort, Mathilde | CCSD

International audience. Background: Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown varia...

Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system

Archive ouverte | Sabathe, C. | CCSD

International audience. Introduction: In relapsing-remitting multiple sclerosis (RRMS), the early identification of suboptimal responders would prevent irreversible disability progression.Objectives: We aimed to dev...

Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

Archive ouverte | Donzé, C. | CCSD

International audience. Objectives: Establish recommendations for the management of UTIs in MS patients.Background: Urinary tract infections (UTIs) are common during multiple sclerosis (MS) and are one of the most c...

Chargement des enrichissements...